Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 123 of 1,261
  1. US 11958893

    Methods for modulating an immune response

    Cue Biopharma, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  2. US 11959081

    Transthyretin (TTR) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  3. US 11959084

    Nucleic acid construct

    AUTOLUS LIMITED Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  4. US 11958840

    Compounds, compositions and methods

    DENALI THERAPEUTICS INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  5. US 11958845

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  6. US 11958850

    Heteroaryl compounds for kinase inhibition

    Takeda Pharmaceutical Company Limited Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  7. US 11958909

    Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

    Sutro Biopharma, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  8. US 11957764

    Protein-type nanoparticles, preparation methods, and application thereof

    South China University of Technology Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  9. US 11957740

    Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency

    Prime Bio, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  10. US 11957683

    Bicyclic compounds

    Aligos Therapeutics, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  11. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  12. US 11957675

    Methods and uses for treating anhedonia

    Xenon Pharmaceuticals Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  13. US 11957686

    Compositions for delivery of reboxetine

    AXSOME THERAPEUTICS, INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  14. US 11957704

    Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors

    REGENERON PHARMACEUTICALS, INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  15. US 11958901

    Anti-CXCR5 antibodies and compositions and uses thereof

    The Regents of the University of California Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  16. US 11958903

    Single-domain antibodies against LAG-3 and uses thereof

    Nanjing Legend Biotech Co., Ltd Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  17. US 11958908

    Compositions and methods for the depletion of CD117+ cells

    CRISPR THERAPEUTICS AG Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  18. US 11958879

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  19. US 11958894

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  20. US 11958910

    Bispecific antigen binding molecules that bind HER2, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  21. US 11957684

    Treatment of heavy menstrual bleeding associated with uterine fibroids

    Takeda Pharmaceutical Company Limited Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  22. US 11959080

    Methods and compositions for inhibiting PMP22 expression

    Ionis Pharmaceuticals, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  23. US 11957736

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    XERIS PHARMACEUTICALS, INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  24. US 11957867

    Syringe stabilizer

    Takeda Pharmaceutical Company Limited Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.